Since 1999 BioTrak has assisted both large and small pharmaceutical companies with their consulting needs. Our senior consulting team brings decades of health care product research and commercialization experience to each project.
Larry A. Risen,
President and CEO
Experience Makes a Difference:
- 24 years medical industry commercial experience
- Project leader/director on over 250 consulting assignments involving drug safety, human factors research, labeling comprehension, product planning, commercial strategy, and commercial support services. This included 15 REMS
assignments, over 45 web-hosted patient and prescriber surveys,
and a broad range of commercial research.
- Managed 20 new product launches – 3 Rx, 17 Dx
- Built 2 specialty pharma commercial programs from ground up
- Designed novel, reliable and predicable methods for REMS assessments
Mr. Risen founded BioTrak in 1999. Prior to BioTrak, Mr. Risen was Vice President of Commercial Development at Cypros Pharmaceutical Corporation (now Questcor) from 1994 to 1999, where he built a sales and marketing organization, coordinated development of a new drug distribution facility, and completed several product licensing deals. Prior to Cypros, Mr. Risen held various management level positions in marketing and product development while at Gen-Probe Inc. and Molecular Biosystems Inc. Mr. Risen received his Bachelor of Science degree in Biology from the University of Iowa and completed his MBA studies at the University of San Diego. He has been a featured speaker at national and regional industry conferences and has authored several articles and videos on REMS assessment, REMS program design, and labeling comprehension studies.
PharmD, Vice President
- 25 years clinical development experience from IND/IDE to NDA/PMA
- Study director for over 50 Phase I to Phase III clinical studies leading to multiple approvals
- Project manager for 4 clinical development programs into Phase III
- Experienced with both remote and web-based EDC systems
- Currently BioTrak’s PharmaTrak™ Vice President and Senior Consultant
Dr. Cremer has 25 years of academic and industry clinical research and regulatory experience in a wide variety of therapeutic areas including oncology, cardiology, pulmonary, neurology, hematology, and infectious diseases. For the last seven years, he has provided clinical research, regulatory and business development consulting services to emerging pharmaceutical and medical device companies. He has held management positions at four medical device and pharmaceutical companies (IVAC, Gensia, Alliance, and Cypros) where he managed domestic and international clinical trials resulting in one drug and two medical device approvals. Prior to his roles in industry, Dr. Cremer was an Assistant Professor at the University of Texas Health Science Center in San Antonio where he taught clinical pharmacy and pharmacokinetics.
Gerard Smits PhD,
Biostatistics and Data Management
Dr. Smits brings over twenty years of biostatistical experience with pharmaceutical, device, and biotech companies, working for 19 years as an independent consultant. He provided statistical support on pre-clinical through phase IV studies on a wide variety of indications (e.g., oncology, renal disease, anemia, heart failure, myocardial infarction, hepatitis B and C, hypertension, insomnia, vision correction, robotic surgical intervention, surgical treatment of obesity, and CNS trauma). His responsibilities have ranged from study design and formulation through statistical analysis, table production, writing of statistical reports, meetings with the FDA as needed, including panel meetings, and have served as a DSMB member. Dr. Smits has managed clinical trials, survey research, and human factors projects. Taught several courses SAS, having 28 years experience with the statistical package. Dr. Smits is proficient with StatXact (exact statistical tests), and PEST (group sequential methods), and R (a general data analysis program) and able to explain complex statistical concepts in terms understandable to non-statisticians.